Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer

David S. Ettinger; Dianne M. Finkelstein; Martin D. Abeloff; Yuang Chi Chang; Thomas J. Smith; Martin M. Oken; John C. Ruckdeschel

doi:10.1007/BF00177255

Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer

David S. Ettinger, Dianne M. Finkelstein, Martin D. Abeloff, Yuang Chi Chang, Thomas J. Smith, Martin M. Oken, John C. Ruckdeschel

School of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.

Original language	English (US)
Pages (from-to)	183-185
Number of pages	3
Journal	Investigational New Drugs
Volume	8
Issue number	2
DOIs	https://doi.org/10.1007/BF00177255
State	Published - May 1990

Keywords

n-methylformamide
small cell lung cancer
spirogermanium

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00177255

Cite this

@article{87cfe37a8d164954b3ca628457d9958f,

title = "Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer",

abstract = "Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.",

keywords = "n-methylformamide, small cell lung cancer, spirogermanium",

author = "Ettinger, {David S.} and Finkelstein, {Dianne M.} and Abeloff, {Martin D.} and Chang, {Yuang Chi} and Smith, {Thomas J.} and Oken, {Martin M.} and Ruckdeschel, {John C.}",

year = "1990",

month = may,

doi = "10.1007/BF00177255",

language = "English (US)",

volume = "8",

pages = "183--185",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer

AU - Ettinger, David S.

AU - Finkelstein, Dianne M.

AU - Abeloff, Martin D.

AU - Chang, Yuang Chi

AU - Smith, Thomas J.

AU - Oken, Martin M.

AU - Ruckdeschel, John C.

PY - 1990/5

Y1 - 1990/5

N2 - Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.

AB - Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.

KW - n-methylformamide

KW - small cell lung cancer

KW - spirogermanium

UR - http://www.scopus.com/inward/record.url?scp=0025280312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025280312&partnerID=8YFLogxK

U2 - 10.1007/BF00177255

DO - 10.1007/BF00177255

M3 - Article

C2 - 2166720

AN - SCOPUS:0025280312

SN - 0167-6997

VL - 8

SP - 183

EP - 185

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this